We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Clinical Data and PharmaCare Sign Landmark Pharmacogenomics Testing Agreement

Clinical Data and PharmaCare Sign Landmark Pharmacogenomics Testing Agreement

Clinical Data and PharmaCare Sign Landmark Pharmacogenomics Testing Agreement

Clinical Data and PharmaCare Sign Landmark Pharmacogenomics Testing Agreement

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Clinical Data and PharmaCare Sign Landmark Pharmacogenomics Testing Agreement"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Clinical Data, Inc. has announced that its PGxHealth Division has signed a landmark pharmacogenomics testing agreement with PharmaCare Management Services, Inc., a wholly-owned subsidiary of CVS Corporation

PGxHealth is developing and commercializing genetics-based tests that help determine how individuals may benefit from a specific drug or drug class.

Under the agreement, PGxHealth will provide pharmacogenomics testing services and assist in incorporating genetic testing into PharmaCare clinical programs to assist in the selection of the safest, efficacious treatments for patients.

Initially, PGxHealth tests associated with clozapine and warfarin will be the focus of this collaboration, and both parties will work to introduce these and other tests to PharmaCare customers as they become available.

In addition, Clinical Data and PharmaCare will jointly explore further partnership opportunities targeting therapeutic areas and disease conditions that may benefit clinically and economically from the introduction of tests based on response and safety biomarkers.

Drew Fromkin, President and CEO of Clinical Data, said, "We are extremely pleased to reach this agreement, and we look forward to working closely with PharmaCare to bring pharmacogenomics tests into the clinic to improve patient care."

"This collaboration marks an exciting and important milestone for our industry because, as the first agreement of its kind, it illustrates the maturation of the science of pharmacogenomics and the growing awareness of the value of incorporating genetic markers into clinical best practices and quality initiatives."

"Together with PharmaCare and other key healthcare constituents, we expect to significantly improve patient outcomes and reduce overall healthcare costs for payers, providers and patients."

"We further believe that PGxHealth's vanguard position in the development of genetic testing, combined with the market reach of PharmaCare, will help catalyze a widespread appreciation of the value of pharmacogenomics as a key tool for healthcare providers."

"This emerging and promising area of healthcare will help us continue to improve patient safety by utilizing cutting edge technology," said Chip Phillips, COO, Specialty Services of PharmaCare.

"We look forward to helping our clients and patients realize improved clinical outcomes as well as cost savings by offering the benefits of pharmacogenomics testing."